BACKGROUND: Gangliosicle GD2 is abundant on human neuroblastoma (NB). Monoclonal antibody 3F8 targeted to GD2 may have imaging and therapeutic potential. Antigen-negative clones can escape immune-mediated attack leading to clinical resistance or recurrence. PROCEDURE: Among 95 evaluable patients treated intravenously with 3F8 (94 Stage 4, 1 Stage 3), 66 received nonradiolabeled 3F8, 11 received 131-iodine-labeled-3F8 (8-28 mCi/kg) with autologous bone marrow rescue, and 18 received both forms of treatment. Prior to treatment, 90 patients tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 68), tumor immunohistochemistry (n = 20), or diagnostic radioimmunoscintigraphy (n = 2). RESULTS: Of 62 patients who had refractory or recurrent neuroblastoma following 3F8 treatment, 61 (98%) tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 51) or tumor immunohistochemistry (n = 10). The sole tumor that lost GD2 expression underwent phenotypic transformation into a pheochromocytoma-like tumor. CONCLUSIONS: The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure.
BACKGROUND: Gangliosicle GD2 is abundant on humanneuroblastoma (NB). Monoclonal antibody 3F8 targeted to GD2 may have imaging and therapeutic potential. Antigen-negative clones can escape immune-mediated attack leading to clinical resistance or recurrence. PROCEDURE: Among 95 evaluable patients treated intravenously with 3F8 (94 Stage 4, 1 Stage 3), 66 received nonradiolabeled 3F8, 11 received 131-iodine-labeled-3F8 (8-28 mCi/kg) with autologous bone marrow rescue, and 18 received both forms of treatment. Prior to treatment, 90 patients tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 68), tumor immunohistochemistry (n = 20), or diagnostic radioimmunoscintigraphy (n = 2). RESULTS: Of 62 patients who had refractory or recurrent neuroblastoma following 3F8 treatment, 61 (98%) tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 51) or tumor immunohistochemistry (n = 10). The sole tumor that lost GD2 expression underwent phenotypic transformation into a pheochromocytoma-like tumor. CONCLUSIONS: The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure.
Authors: Rosa Nguyen; Xiyuan Zhang; Ming Sun; Shahroze Abbas; Charlie Seibert; Michael C Kelly; Jack F Shern; Carol J Thiele Journal: Clin Cancer Res Date: 2022-09-01 Impact factor: 13.801
Authors: Kim Kramer; Brian H Kushner; Shakeel Modak; Neeta Pandit-Taskar; Peter Smith-Jones; Pat Zanzonico; John L Humm; Hong Xu; Suzanne L Wolden; Mark M Souweidane; Steven M Larson; Nai-Kong V Cheung Journal: J Neurooncol Date: 2009-11-05 Impact factor: 4.130
Authors: Michael Roth; Marissa Linkowski; John Tarim; Sajida Piperdi; Rebecca Sowers; David Geller; Jonathan Gill; Richard Gorlick Journal: Cancer Date: 2013-10-25 Impact factor: 6.860
Authors: Renske J E van den Bijgaart; Michiel Kroesen; Ingrid C Brok; Daphne Reijnen; Melissa Wassink; Louis Boon; Peter M Hoogerbrugge; Gosse J Adema Journal: Oncoimmunology Date: 2020-09-20 Impact factor: 8.110